News - ROS1 mutation - LARVOL VERI

17d

Association of pre-existing conditions with major driver mutations and PD-L1 expression in NSCLC. (PubMed, BMJ Open Respir Res)

This large-scale, cross-sectional study reveals a complex interplay between genetic mutations, immunological features and pre-existing conditions in NSCLC patients, offering insights that could inform personalised treatment strategies.

17 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

PD-L1 expression • EGFR mutation • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • ROS1 mutation

17d

Crizotinib Associated Renal Abscess --A Case Report- (PubMed, Hinyokika Kiyo)

Her blood test showed a high c-reactive protein (CRP) levels ; therefore, she was admitted and received levofloxacin drip infusion for 5 days. Pathology of the left kidney revealed a renal abscess, but there was no sign of malignancy. Crizotinib has been reported to cause rare adverse effects, such as polycystic renal lesions or renal abscesses.

17 days ago

Journal

ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CEACAM5 (CEA Cell Adhesion Molecule 5) • CRP (C-reactive protein)

ROS1 mutation

Xalkori (crizotinib)

Molecular characterization of adult non-glioblastoma central nervous system (CNS) tumors to identify potential targettable alterations (AIOM 2024)

4 pts received TT at recurrence, within clinical trials: one with grade 3 meningioma and ALK rearrangement treated with alectinib, one with PTCH1 mutant medulloblastoma treated with vismodegib, and two with high TMB treated with nivolumab/ipilumumab. The incidence of targettable molecular alterations in adult CNS tumor patients was lower than in GBM. Nevertheless, in a few selected cases TT have the potential to increase treatment options at recurrence and improve outcomes.

1 month ago

Clinical • Tumor mutational burden • BRCA Biomarker • PD(L)-1 Biomarker • IO biomarker

BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • MET (MET proto-oncogene, receptor tyrosine kinase) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • FGFR1 (Fibroblast growth factor receptor 1) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • NF1 (Neurofibromin 1) • POLE (DNA Polymerase Epsilon) • MDM2 (E3 ubiquitin protein ligase) • PTCH1 (Patched 1) • NF2 (Neurofibromin 2) • BRCA (Breast cancer early onset) • NTRK (Neurotrophic receptor tyrosine kinase)

BRAF V600E • BRCA2 mutation • BRCA1 mutation • TMB-H • PIK3CA mutation • MET amplification • ALK rearrangement • FGFR1 amplification • POLE mutation • NF1 mutation • MDM2 amplification • RET mutation • PTCH1 mutation • NF2 mutation • ROS1 mutation • BRCA mutation • ALK rearrangement + PIK3CA mutation • PTCH1 rearrangement • NTRK fusion

FoundationOne® CDx

Opdivo (nivolumab) • Yervoy (ipilimumab) • Alecensa (alectinib) • Erivedge (vismodegib)

The Effectiveness and Safety of Sintilimab Plus Bevacizumab Combined with Pemetrexed and Platinum-Based Drugs in Retrospective Analysis for Advanced Non-Small Cell Lung Cancer Patients Without Targeted Therapy (ChiCTR2400089107)

P4, N=100, Not yet recruiting, Anhui Chest Hospital; Anhui Chest Hospital

1 month ago

New P4 trial • Metastases

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

ALK fusion • ALK mutation • RET mutation • ROS1 fusion • ROS1 mutation

Avastin (bevacizumab) • Tyvyt (sintilimab) • pemetrexed

3ms

KEYNOTE A60: NT-I7 (Efineptakin Alfa) in Combination with Pembrolizumab in Participants with Advanced Solid Tumors (clinicaltrials.gov)

P1/2, N=215, Active, not recruiting, NeoImmuneTech | Trial completion date: Mar 2025 --> Dec 2024

3 months ago

Trial completion date • Combination therapy • Metastases

BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

EGFR mutation • BRAF mutation • ALK translocation • ROS1 mutation

Keytruda (pembrolizumab) • Hyleukin-7 (efineptakin alfa)

3ms

Novel therapies for pediatric low grade glioma. (PubMed, Curr Opin Neurol)

Historical treatment options in pediatric low-grade gliomas have utilized surgery, radiation therapy and conventional chemotherapy. Recently greater insight into their biology has found that alterations in MAPK driven pathways are often the hallmark of tumorigenesis. Targeting these novel pathways has led to tumor control and shrinkage without the use of conventional chemotherapy. Caution should be taken however, since these treatment options are still novel, and we do not fully appreciate the long-term effects. Nonetheless a new era of targeted medicine is here.

3 months ago

Journal

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • FGFR (Fibroblast Growth Factor Receptor) • NTRK (Neurotrophic receptor tyrosine kinase) • PRKCA (Protein Kinase C Alpha)

BRAF V600E • BRAF V600 • FGFR fusion • BRAF fusion • ROS1 mutation • ROS1 amplification • NTRK fusion

3ms

Clinical Utility of Circulating Tumor DNA for Detecting Lung Cancer Mutations by Targeted Next-Generation Sequencing With Insufficient Tumor Samples. (PubMed, J Clin Lab Anal)

Identifying ctDNA mutations by targeted sequencing in plasma is feasible, showing the clinical value of ctDNA-targeted sequencing in NSCLC patients when tumor tissue sampling is insufficient or even impossible.

3 months ago

Journal • Next-generation sequencing • Circulating tumor DNA

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TYK2 (Tyrosine Kinase 2)

TP53 mutation • EGFR mutation • BRAF mutation • ROS1 mutation

5ms

Enhancing Clinical Utility: Oncomine Dx Target Test Augments Biomarker Detection in Advanced Non-Small-Cell Lung Cancer (IASLC-WCLC 2024)

Conclusions : The integration of ODxTT alongside single gene tests provides significant additional information without compromising the performance of single gene tests. With ODxTT's high success rate, this integration expands the scope of comprehensive therapeutic strategies for advanced lung cancer.

5 months ago

Clinical • Metastases

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MET (MET proto-oncogene, receptor tyrosine kinase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • FGFR3 (Fibroblast growth factor receptor 3) • MAP2K1 (Mitogen-activated protein kinase kinase 1)

BRAF V600E • EGFR mutation • KRAS G12C • BRAF V600 • EGFR T790M • RET fusion • EGFR exon 20 insertion • MET exon 14 mutation • ALK mutation • KRAS G12 • EGFR exon 20 mutation • ROS1 mutation • FGFR3 fusion

Oncomine™ Dx Target Test

8ms

The association of ROS1 mutation with cancer immunity and its impact on the efficacy of pan-cancer immunotherapy. (PubMed, J Transl Med)

No abstract available

8 months ago

Journal • IO biomarker • Pan tumor

ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

ROS1 mutation

9ms

KEYNOTE A60: NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (clinicaltrials.gov)

P1/2, N=215, Active, not recruiting, NeoImmuneTech | Trial completion date: Jun 2024 --> Mar 2025 | Trial primary completion date: Jun 2024 --> Nov 2024 | Recruiting --> Active, not recruiting

9 months ago

Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy • Metastases

BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

EGFR mutation • BRAF mutation • ALK translocation • ROS1 mutation

Keytruda (pembrolizumab) • Hyleukin-7 (efineptakin alfa)

10ms

Mechanisms of Resistance to Tyrosine Kinase Inhibitors in ROS1 Fusion-Positive Nonsmall Cell Lung Cancer. (PubMed, Clin Chem)

This study provided a comprehensive portrait of TKI-resistance mechanisms in ROS1+ NSCLC patients. Using in silico simulations of TKI activity, novel secondary mutations that may confer TKI resistance were identified and may support clinical therapeutic decision-making.

10 months ago

Journal

MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CD74 (CD74 Molecule) • SLC34A2 (Solute carrier family 34 member 2)

MET amplification • ROS1 fusion • ROS1 positive • ROS1 G2032R • ROS1 mutation

Xalkori (crizotinib) • Rozlytrek (entrectinib) • Lorbrena (lorlatinib)

10ms

PBRM1 presents a potential ctDNA marker to monitor response to neoadjuvant chemotherapy in cervical cancer. (PubMed, iScience)

In vitro, PBRM1 knockdown promoted resistance to cisplatin through boosting STAT3 signaling in cervical cancer cells, while it sensitized tumor cells to poly-ADP-ribose-polymerase inhibitor olaparib. These findings suggest that mutant PBRM1 is a potential ctDNA marker of emerging resistance to NACT and of increased sensitivity to olaparib, which warrants further clinical validation.

10 months ago

Journal • PARP Biomarker • Circulating tumor DNA

ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • PBRM1 (Polybromo 1) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase)

PBRM1 mutation • ROS1 mutation • SETD2 mutation

Lynparza (olaparib) • cisplatin

10ms

First-line chemoimmunotherapy and immunotherapy in patients with non-small cell lung cancer and brain metastases: a registry study. (PubMed, Front Oncol)

No demonstrable difference in survival or TTE was seen between receipt of upfront local therapy. Prospective studies are required to assist clinical decision making regarding optimal sequencing of local and systemic therapies.

10 months ago

Journal • PD(L)-1 Biomarker • IO biomarker

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

ALK mutation • ROS1 mutation

10ms

Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors (clinicaltrials.gov)

P1/2, N=22, Active, not recruiting, Coherus Biosciences, Inc. | Recruiting --> Active, not recruiting | N=100 --> 22

10 months ago

Enrollment closed • Enrollment change • Combination therapy • Metastases

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

EGFR mutation • ALK mutation • MET mutation • ROS1 mutation

Loqtorzi (toripalimab-tpzi) • JS006

10ms

PBF-1129 in Patients With NSCLC (clinicaltrials.gov)

P1, N=18, Active, not recruiting, Palobiofarma SL | Trial completion date: Dec 2023 --> Aug 2024 | Trial primary completion date: Oct 2023 --> May 2024

10 months ago

Trial completion date • Trial primary completion date • Metastases

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

ALK mutation • ROS1 mutation

PBF-1129

12ms

Non-invasive decision support for clinical treatment of NSCLC using a multiscale radiomics approach. (PubMed, Radiother Oncol)

We validated multiscale radiomic signatures across tumor genotypes and immunophenotypes in a multi-institutional cohort. This imaging-based biomarker offers a non-invasive approach to select patients with NSCLC who are sensitive to targeted therapies or immunotherapy, which is promising for developing personalized treatment strategies during therapy.

12 months ago

Journal • PD(L)-1 Biomarker • IO biomarker

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • PD-1 (Programmed cell death 1)

TP53 mutation • EGFR mutation • PIK3CA mutation • ALK mutation • ROS1 mutation

12ms

Comparison of Clinical and Genetic Characteristics Between Younger and Older Lung Cancer Patients. (PubMed, Arch Bronconeumol)

Lung cancer displays differences by age at diagnosis which may have important implications for its clinical management.

12 months ago

Journal

HER-2 (Human epidermal growth factor receptor 2) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

HER-2 mutation • ALK translocation • ROS1 mutation

12ms

PIKACHU: PD-1 Antibody Plus Chemotherapy for TKI Failure Driver Gene Mutation Positive Advanced NSCLC (clinicaltrials.gov)

P=N/A, N=100, Recruiting, Hunan Province Tumor Hospital | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2022 --> Dec 2024

12 months ago

Trial completion date • Trial primary completion date • IO biomarker • Metastases

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

EGFR mutation • ALK positive • ALK mutation • ROS1 positive • ROS1 mutation

1year

A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer. (PubMed, Br J Cancer)

Cadonilimab 10 mg/kg Q3W plus anlotinib showed manageable safety and promising efficacy as a first-line chemo-free treatment for advanced NSCLC.

1 year ago

P1/2 data • Journal • PD(L)-1 Biomarker • IO biomarker • Metastases

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)

EGFR mutation • ALK mutation • ROS1 mutation

Focus V (anlotinib) • Kaitanni (cadonilimab)

1year

Clinical analysis of lung adenocarcinoma with epidermal growth factor receptor mutation transformed into sarcoma (PubMed, Zhonghua Jie He He Hu Xi Za Zhi)

We reported a patient with lung adenocarcinoma who developed EGFR-T790M mutation after first-line treatment with icotinib and sarcoma transformation after second-line treatment with almonertinib. Sarcoma transformation can be one of the forms of drug resistance in patients with lung adenocarcinoma with EGFR-TKIs. The prognosis of patients with adenocarcinoma after transformation into sarcoma is poor.

1 year ago

Journal • IO biomarker

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

EGFR mutation • EGFR T790M • ALK mutation • ROS1 mutation

Conmana (icotinib) • Ameile (aumolertinib)

1year

Consolidation therapy of Adebrelimab for stage III unresectable NSCLC after concurrent radiotherapy and chemotherapy (cCRT combined with or without Adebrelimab) (ChiCTR2300075011)

P4, N=120, Recruiting, Shandong First Medical University Affiliated Cancer Hospital; Shandong First Medical University Affiliated Cancer Hospital

1 year ago

New P4 trial

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

MET amplification • ALK fusion • ALK mutation • MET mutation • ROS1 mutation • EGFR negative

cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • Ariely (adebrelimab)

1year

KEYNOTE A60: NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (clinicaltrials.gov)

P1/2, N=238, Recruiting, NeoImmuneTech | Phase classification: P1b/2a --> P1/2

1 year ago

Phase classification • Combination therapy • Metastases

BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

EGFR mutation • BRAF mutation • ALK translocation • ROS1 mutation

Keytruda (pembrolizumab) • Hyleukin-7 (efineptakin alfa)

1year

CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer (clinicaltrials.gov)

P1/2, N=242, Recruiting, Roswell Park Cancer Institute | Trial completion date: Dec 2023 --> Dec 2027 | Trial primary completion date: Dec 2023 --> Dec 2027

1 year ago

Trial completion date • Trial primary completion date • Combination therapy • Pan tumor • Metastases

PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

PD-L1 expression • ALK mutation • ROS1 mutation

Keytruda (pembrolizumab) • Opdivo (nivolumab) • CimaVax EGF (EGF-PTI)

1year

Genomic and transcriptomic analyses of thyroid cancers identify DICER1 somatic mutations in adult follicular-patterned RAS-like tumors. (PubMed, Front Endocrinol (Lausanne))

Furthermore, we identified DICER1 mutations, one of which is previously unreported in thyroid lesions. For these less common alterations and for patients with unknown drivers, we provide signaling information applying TCGA-derived classification.

1 year ago

Retrospective data • Journal

BRAF (B-raf proto-oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • RAS (Rat Sarcoma Virus) • DICER1 (Dicer 1 Ribonuclease III)

BRAF V600E • BRAF V600 • RAS mutation • ROS1 mutation

1year

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors. (PubMed, EMBO Mol Med)

In vivo experiments showed that ROS1 D2113N induced tumor formation that was sensitive to crizotinib and lorlatinib, FDA-approved ROS1-TKIs. Collectively, these findings highlight the tumorigenic potential of specific point mutations within the ROS1 kinase domain and their potential as therapeutic targets with FDA-approved ROS1-TKIs.

1 year ago

Journal

ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

ROS1 fusion • ROS1 mutation

Xalkori (crizotinib) • Lorbrena (lorlatinib)

1year

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer (clinicaltrials.gov)

P1, N=56, Active, not recruiting, National Cancer Institute (NCI) | Trial primary completion date: Nov 2024 --> Oct 2023

1 year ago

Trial primary completion date

PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CD4 (CD4 Molecule)

BRAF V600 • ALK mutation • ROS1 mutation

Keytruda (pembrolizumab)

1year

A retrospective study of the prevalence and clinical outcomes of KRAS G12C mutated advanced non-small cell lung cancer (NSCLC) in Australian patients (pts) (ESMO Asia 2023)

The KRAS G12C, KRAS other and KRAS WT cohorts had similar patient and treatment patterns, although smoking history was more common in pts with a KRAS mutation. In the absence of other key driver mutations, there was no significant difference in mOS between cohorts.

1 year ago

Clinical data • Retrospective data • PD(L)-1 Biomarker • IO biomarker • Metastases

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

KRAS mutation • EGFR mutation • KRAS G12C • KRAS wild-type • ALK mutation • RAS wild-type • KRAS G12 • ROS1 mutation

1year

Cost-Consequence of Using NGS vs Single-Testing in NSCLC Patients at Diagnosis – Real-World Data From a Portuguese Hospital (ISPOR-EU 2023)

NGS testing in NSCLC patients allows for the detection of multiple additional gene alterations, which have the potential to inform therapeutic decision-making. Based on the current number of actionable oncogenes and ongoing clinical trials investigating new ones, NGS is potentially cost-saving compared to sequential testing for all known targetable genomic alterations. Further studies should be conducted to validate this hypothesis.

1 year ago

Clinical • Real-world evidence • Next-generation sequencing • Real-world

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

EGFR mutation • ALK mutation • ROS1 mutation

1year

Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3 (clinicaltrials.gov)

P2, N=16, Completed, Wake Forest University Health Sciences | Trial completion date: Apr 2018 --> Oct 2022

1 year ago

Trial completion date • Metastases

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

ROS1 mutation

pemetrexed

1year

Concordance on treatment recommendations from multidisciplinary tumor boards – Data from driver-mutated lung cancer patients in focus (DGHO 2023)

Patients with a concordant treatment had a significant longer OS as patients with a discordant treatment. The concordance rate was higher in the group of driver-mutated patients and patients with a driver-mutation and a concordant treatment showed a longer OS as patients without. Assessment of concordance to MTB recommendations could become a meaningful and reproducible quality criterion for cancer centers in Germany.

1 year ago

Clinical • Discordant

EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • EML4 (EMAP Like 4)

EGFR mutation • BRAF mutation • ALK translocation • ROS1 mutation

1year

Survival and Therapy Analysis of Non-small cell lung cancer (NSCLC) patients with small-scale ROS1 Mutations (DGHO 2023)

The cohort’s clinical characteristics contrasted ROS1 -fused cohorts. Co-occurrence of KRAS mutations led to shortened survival and patients benefited from ICB. Our data does not support the idea of ROS1 small-scale mutations as strong oncogenic drivers in NSCLC, but rather as relevant bystanders altering the efficacy of treatment approaches.

1 year ago

Clinical

EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • FGFR1 (Fibroblast growth factor receptor 1)

TP53 mutation • EGFR mutation • PIK3CA mutation • KRAS G12V • FGFR1 mutation • ROS1 fusion • KRAS G12 • ROS1 mutation • MET fusion

1year

A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors (clinicaltrials.gov)

P2, N=120, Not yet recruiting, Chongqing University Cancer Hospital

1 year ago

New P2 trial

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

EGFR mutation • ALK mutation • ROS1 mutation

AiRuiKa (camrelizumab) • capecitabine • AiRuiYi (fluzoparib)

over1year

Clinicopathologic and molecular characteristics of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients. (PubMed, Lung Cancer)

The cohort's clinical characteristics contrasted ROS1-fused cohorts. Co-occurrence of KRAS mutations led to shortened survival and patients benefited from ICB. Our data does not support the idea of ROS1 small-scale mutations as strong oncogenic drivers in NSCLC, but rather as relevant bystanders altering the efficacy of treatment approaches.

over 1 year ago

Journal

TP53 mutation • EGFR mutation • PIK3CA mutation • FGFR1 mutation • ROS1 fusion • ROS1 mutation

over1year

Real-world survival outcomes of first line pembrolizumab plus chemotherapy for metastatic Non-Small Cell Lung Cancer (NSCLC) in Australia (COSA 2023)

This retrospective study aimed to evaluate the mortality risk and overall survival (OS) of metastatic NSCLC patients who received first-line pembrolizumab plus carboplatin doublet chemotherapy or pembrolizumab alone — aligned with KEYNOTE-189 and KEYNOTE-024 trials, in the real-world setting of oncology practice in Australia. The real-world survival outcomes for metastatic NSCLC patients was inferior in the pembrolizumab-chemotherapy group but pembrolizumab alone conveyed survival benefit comparable to trial results.

over 1 year ago

Clinical • Real-world evidence • PD(L)-1 Biomarker • IO biomarker • Real-world • Metastases

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

EGFR mutation • ALK mutation • ROS1 mutation • PD-L1-L

Keytruda (pembrolizumab) • carboplatin

over1year

Mutational landscape and predictors of survival in head and neck mucosal melanoma. (PubMed, Int Forum Allergy Rhinol)

A molecular subset (∼13%) has ROS1 mutations, which is an actionable driver mutation. ROS1-mutated patients have improved overall survival likely due to high mutational burden.

over 1 year ago

Journal • Tumor mutational burden

TMB (Tumor Mutational Burden) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

TMB-H • TMB-L • ROS1 mutation

over1year

Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3 (clinicaltrials.gov)

P2, N=16, Completed, Wake Forest University Health Sciences | Active, not recruiting --> Completed

over 1 year ago

Trial completion • Metastases

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

ROS1 mutation

pemetrexed

over1year

A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)

P3, N=643, Active, not recruiting, Shanghai Henlius Biotech | Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2023 --> Oct 2023

over 1 year ago

Enrollment closed • Trial primary completion date • Combination therapy • Tumor mutational burden • IO biomarker • Metastases

PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

PD-L1 expression • ALK mutation • ROS1 mutation

carboplatin • pemetrexed • Hetronifly (serplulimab) • Hanbeitai (bevacizumab biosimilar)

over1year

Survival and therapy analysis of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients (ESMO 2023)

Co-occurrence of KRAS mutations led to shortened survival and patients benefited from ICB. Our data does not support the idea of ROS1 small-scale mutations as strong oncogenic drivers in NSCLC, but rather as relevant bystanders altering the efficacy of treatment approaches.

over 1 year ago

Clinical

TP53 mutation • EGFR mutation • PIK3CA mutation • KRAS G12V • FGFR1 mutation • ROS1 fusion • KRAS G12 • ROS1 mutation • MET fusion

over1year

ROS1 mutations as potential negative predictor for response of immunotherapy in patient with head and neck cancer (ESMO 2023)

Conclusions We identified that ROS1 mutation predicted the resistance to ICIs in HNSCs. The clinical delivery of ICIs should be cautious in those patients.

over 1 year ago

Clinical • IO biomarker

TMB (Tumor Mutational Burden) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

TMB-H • ROS1 rearrangement • ROS1 mutation • ROS1 wild-type

over1year

The Association of Acinar Pattern with Clinicopathological, Molecular Features, and Prognosis in Lung Adenocarcinoma Patients (IASLC-WCLC 2023)

This study represents a comprehensive clinical investigation of LUAD patients with tumors harboring <5%, 5-45%, and 50% of acinar separately. The results show that LUAD patients with 50% acinar have significantly worse OS than patients with 5-45% acinar. This study also shows that having at least a 5% acinar component is an independent indicator of poor prognosis in LUAD.

over 1 year ago

Clinical

EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

KRAS mutation • EGFR mutation • KRAS G12C • BRAF mutation • ALK rearrangement • RET mutation • MET mutation • KRAS G12 • ROS1 mutation

over1year

Concordance on Treatment Recommendations from Multidisciplinary Tumor Boards -Data from Driver-Mutated Lung Cancer in Focus (IASLC-WCLC 2023)

over 1 year ago

Discordant

EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • EML4 (EMAP Like 4)

EGFR mutation • BRAF mutation • ALK translocation • ROS1 mutation

over1year

Screening biomarkers for predicting the efficacy of immunotherapy in patients with PD-L1 overexpression. (PubMed, J Cancer Res Clin Oncol)

We have established a model that can predict the efficacy of ICIs immunotherapy in PD-L1 positive patients. The model consists of ROS1 gene mutations, KRAS gene mutations, tumor staging, and endocrine system disease history, and has good predictive ability.

over 1 year ago

Journal • PD(L)-1 Biomarker • IO biomarker

KRAS (KRAS proto-oncogene GTPase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

KRAS mutation • PD-L1 overexpression • ROS1 mutation